{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:02:32Z","timestamp":1779688952772,"version":"3.53.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Approximately 2% of patients with inflammatory bowel disease (IBD) have primary sclerosing cholangitis (PSC), and some require liver transplantation (LT). Managing IBD after LT is challenging given concomitant anti-rejection immunotherapies. We report our experience using upadacitinib (UPA) to treat patients with IBD after LT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, single-center observational study at a tertiary center, identifying patients after LT who received UPA. We assessed efficacy and safety of UPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four patients after LT (Crohn\u2019s disease\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; ulcerative colitis\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) received UPA for IBD control (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) or as a steroid-sparing adjunct for anti-rejection (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), alongside anti-rejection immunosuppression. Median follow-up from UPA initiation was 10.5\u00a0months (IQR 8.9\u201314.6); age 41.5\u00a0years (IQR 40\u201344); interval from LT 3.2\u00a0years (IQR 2.3\u20135.6). Two receiving prednisone for Crohn\u2019s control at baseline achieved steroid-free remission (Harvey\u2013Bradshaw Index\u2009&lt;\u20095). Three developed liver enzyme elevation: one stopped UPA at one month with subsequent normalization of alanine and aspartate aminotransferase; one underwent liver biopsy showing no rejection and continued UPA with 9-month follow-up; and one receiving UPA for potential anti-organ rejection plus vedolizumab ultimately discontinued UPA for suspected rejection after tapering steroids. One patient experienced mild COVID-19 that resolved without treatment change. No life-threatening adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small series, UPA controlled IBD activity in 2 of 4 patients after LT but was associated with liver-enzyme elevations in 3, prompting discontinuation in 2. These findings support cautious, closely monitored use and highlight the need for a larger multi-center study of UPA in patients with IBD after LT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10620-025-09569-9","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:20:36Z","timestamp":1763616036000},"page":"1711-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series"],"prefix":"10.1007","volume":"71","author":[{"given":"Yusuke","family":"Miyatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I.","family":"Aronsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"9569_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024;18:1\u201337. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad108.","journal-title":"J Crohns Colitis."},{"key":"9569_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77:659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology."},{"key":"9569_CR3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","volume":"161","author":"B Barberio","year":"2021","unstructured":"Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161:1865\u20131877. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.032.","journal-title":"Gastroenterology."},{"key":"9569_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"EASL Clinical Practice Guidelines on sclerosing cholangitis","year":"2022","unstructured":"EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77:761\u2013806. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.011.","journal-title":"J Hepatol."},{"key":"9569_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","volume":"20","author":"JR Hov","year":"2023","unstructured":"Hov JR, Karlsen TH. The microbiota and the gut-liver axis in primary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol. 2023;20:135\u2013154. https:\/\/doi.org\/10.1038\/s41575-022-00690-y.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9569_CR6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.transproceed.2012.07.098","volume":"44","author":"F Gelley","year":"2012","unstructured":"Gelley F, Miheller P, P\u00e9ter A, Telkes G, Nemes B. Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience. Transplant Proc. 2012;44:2164\u20132165. https:\/\/doi.org\/10.1016\/j.transproceed.2012.07.098.","journal-title":"Transplant Proc."},{"key":"9569_CR7","doi-asserted-by":"publisher","unstructured":"Taneja V, Anand RS, El-Dallal M, et al. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2023;https:\/\/doi.org\/10.1093\/ibd\/izad108","DOI":"10.1093\/ibd\/izad108"},{"key":"9569_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al. Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease. N Engl J Med. 2023;388:1966\u20131980. https:\/\/doi.org\/10.1056\/NEJMoa2212728.","journal-title":"N Engl J Med."},{"key":"9569_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128. https:\/\/doi.org\/10.1016\/s0140-6736(22)00581-5.","journal-title":"Lancet."},{"key":"9569_CR10","doi-asserted-by":"publisher","unstructured":"Assadiasl S, Mojtahedi H, Nicknam MH. JAK Inhibitors in Solid Organ Transplantation. J Clin Pharmacol. Jul 27 2023;https:\/\/doi.org\/10.1002\/jcph.2325","DOI":"10.1002\/jcph.2325"},{"key":"9569_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","volume":"81","author":"EASL Clinical Practice Guidelines on liver transplantation","year":"2024","unstructured":"EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81:1040\u20131086. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.032.","journal-title":"J Hepatol."},{"key":"9569_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cld.2022.08.006","volume":"27","author":"JB Henson","year":"2023","unstructured":"Henson JB, Muir AJ. Evaluation of an Abnormal Liver Panel After Liver Transplantation. Clin Liver Dis. 2023;27:103\u2013115. https:\/\/doi.org\/10.1016\/j.cld.2022.08.006.","journal-title":"Clin Liver Dis."},{"key":"9569_CR13","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0\u00a0years of treatment. Aliment Pharmacol Ther. 2022;55:464\u2013478. https:\/\/doi.org\/10.1111\/apt.16712","DOI":"10.1111\/apt.16712"},{"key":"9569_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1172\/jci23640","volume":"115","author":"C Klein","year":"2005","unstructured":"Klein C, W\u00fcstefeld T, Assmus U et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest. 2005;115:860\u2013869. https:\/\/doi.org\/10.1172\/jci23640.","journal-title":"J Clin Invest."},{"key":"9569_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jcph.1414","volume":"59","author":"S Trueman","year":"2019","unstructured":"Trueman S, Mohamed MF, Feng T, Lacerda AP, Marbury T, Othman AA. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics. J Clin Pharmacol. 2019;59:1188\u20131194. https:\/\/doi.org\/10.1002\/jcph.1414.","journal-title":"J Clin Pharmacol."},{"key":"9569_CR16","doi-asserted-by":"publisher","unstructured":"Meunier L, Clerc C, Meszaros M. Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient. J Crohns Colitis. Apr 6 2021;15:695. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa032","DOI":"10.1093\/ecco-jcc\/jjaa032"},{"key":"9569_CR17","doi-asserted-by":"publisher","unstructured":"Con D, Hilley P, Chin S, et al. Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation. J Crohns Colitis. 2024;https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae039","DOI":"10.1093\/ecco-jcc\/jjae039"},{"key":"9569_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000000819","volume":"4","author":"S Busque","year":"2018","unstructured":"Busque S, Vincenti FG, Tedesco Silva H et al. Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. Transplant Direct. 2018;4:e380. https:\/\/doi.org\/10.1097\/txd.0000000000000819.","journal-title":"Transplant Direct."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09569-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09569-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09569-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:06:07Z","timestamp":1779685567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09569-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["9569"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09569-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YM has received consultant fee from Takeda.  D. Choi has served on the speaker bureau for Janssen Pharmaceuticals, Abbvie, Eli Lilly; and has served as a consultant to Bristol Myers Squibb, and Boehringer Ingelheim, Abbvie, Eli Lilly, Janssen Pharmaceuticals, Pfizer. AIA has nothing to disclose. AP has nothing to disclose RDC serves on the speakers bureau for Abbvie and has served as a consultant for Abbvie, Bausch Health, BMS, Eli Lilly, Genentech, Gilead Sciences, Johnson & Johnson, Pfizer, and Takeda. DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Abivax SA, Altrubio, Athos Therapeutics, Inc, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, and Ventyx.  Board of Directors: Cornerstones Health (non-profit), iUSCAN (non-profit).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, with approval from the Institutional Review Board at the University of Chicago.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}